Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to Post FY2021 Earnings of ($1.32) Per Share, Svb Leerink Forecasts

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) – Research analysts at Svb Leerink issued their FY2021 earnings estimates for Adaptimmune Therapeutics in a research report issued on Monday, January 13th. Svb Leerink analyst J. Chang expects that the biotechnology company will post earnings per share of ($1.32) for the year.

A number of other brokerages have also recently commented on ADAP. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. Finally, ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.23.

Shares of Adaptimmune Therapeutics stock opened at $4.04 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.93 and a quick ratio of 3.93. The business’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.74. The stock has a market capitalization of $139.24 million, a P/E ratio of -4.21 and a beta of 1.83. Adaptimmune Therapeutics has a one year low of $0.71 and a one year high of $6.00.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $7.00 million.

Several hedge funds have recently modified their holdings of ADAP. Man Group plc grew its position in shares of Adaptimmune Therapeutics by 37.4% in the 2nd quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 500,595 shares during the last quarter. Bamco Inc. NY grew its position in shares of Adaptimmune Therapeutics by 6.1% in the 2nd quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock worth $694,000 after buying an additional 10,000 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Adaptimmune Therapeutics by 21,372.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock worth $32,000 after buying an additional 21,372 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of Adaptimmune Therapeutics by 5.2% in the 3rd quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock worth $1,380,000 after buying an additional 45,249 shares during the last quarter. Hedge funds and other institutional investors own 65.06% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: Neutral Rating

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit